Magenta therapeutics, inc. (MGTA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Revenue

0

0

0

0

0

0

0

0

0

0

0

Operating expenses:
Research and development

13,963

18,714

16,524

13,433

10,537

12,390

11,418

9,683

7,849

5,210

13,816

General and administrative

7,281

5,923

6,120

5,905

5,813

5,540

5,284

4,342

3,457

1,805

1,915

Total operating expenses

21,244

24,637

22,644

19,338

16,350

17,930

16,702

14,025

11,306

7,015

15,731

Loss from operations

-21,244

-24,637

-22,644

-19,338

-16,350

-17,930

-16,702

-14,025

-11,306

-7,015

-15,731

Interest and other income, net

1,233

1,400

1,654

1,630

1,516

1,251

687

365

145

102

-

Net loss

-20,011

-23,237

-20,990

-17,708

-14,834

-16,679

-16,015

-13,660

-11,161

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

88

-

6

207

Cumulative dividends on redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

83

Reversal of cumulative dividends on redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

634

Net loss attributable to common stockholders

-

-

-20,990

-17,708

-

-16,679

-16,015

-13,748

-11,161

-6,919

-15,387

Net loss per share, basic and diluted

-0.51

-0.61

-0.54

-0.48

-0.44

5.02

-0.49

-3.13

-4.53

-3.44

-8.90

Weighted average common shares outstanding, basic and diluted

39,364

39,150

38,824

36,662

33,422

33,703

32,997

4,391

2,466

2,009

1,728

Comprehensive loss:
Net loss

-20,011

-23,237

-20,990

-17,708

-14,834

-16,679

-16,015

-13,660

-11,161

-

-

Other comprehensive income:
Unrealized gains on marketable securities

355

-75

-56

98

49

-

-

-

-

-

-

Total other comprehensive income

355

-75

-56

98

49

-

-

-

-

-

-

Total comprehensive loss

-19,656

-23,312

-21,046

-17,610

-14,785

-16,687

-16,015

-13,660

-11,161

-6,913

-15,731